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Abstract 36 
The aim of this study was to evaluate the in vitro steroid sensitivity as predictor of clinical 37 
response to glucocorticoids in childhood idiopathic nephrotic syndrome (INS). Seventy-four 38 
patients (median age 4.33, IQR 2.82-7.23; 63.5% male) were enrolled in a prospective 39 
multicenter study: in vitro steroid inhibition of patients’ peripheral blood mononuclear cell 40 
proliferation was evaluated by [methyl-3H] thymidine incorporation assay at disease onset (T0) 41 
and after 4 weeks (T4) of treatment. Steroid dependence was associated with increased in vitro 42 
sensitivity at T4 assessed both as drug concentration inducing 50% of inhibition (IC50; OR=0.48, 43 
95%CI=0.24–0.85; p-value=0.0094) and maximum inhibition at the highest drug concentration 44 
(Imax; OR=1.13, 95%CI=1.02-1.31; p-value=0.017). IC50 > 4.4nM and Imax < 92% at T4 were good 45 
predictors for optimal clinical response. These results suggest that this test may be useful for 46 
predicting the response to glucocorticoid therapy in pediatric INS. 47 
 48 
INTRODUCTION 49 
Idiopathic nephrotic syndrome (INS) is a rare childhood kidney disease (2-7 cases per year per 50 
100.000 age related population) (1-3). Steroids represent the best first-line therapeutic option, 51 
inducing remission in 90% of patients (steroid sensitive – SS) (1, 4, 5). Within those patients, 52 
after an initial response to prednisone, almost 40-50% show frequent relapses or become 53 
steroid dependent (FR-SD), while the rest of the patients will never relapse or will show 54 
infrequent relapses (NR-IR), presenting an optimal response to steroid treatment. Moreover 55 
10% of patients will never respond and are therefore steroid resistant (SR). Steroid 56 
responsiveness is of major prognostic importance: patients with steroid dependence and 57 
resistance are at risk of more aggressive treatment and disease related complications (6, 7). 58 
Many efforts have been made to predict steroid response in children with INS, however, to date, 59 
no definite prognostic factor has been defined (1, 8-12). 60 
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Peripheral blood mononuclear cells (PBMCs), in particular T lymphocytes, are involved in the 61 
immunosuppressive effects of steroids and the in vitro steroid-mediated inhibition of mitogen-62 
stimulated PBMCs has been used to investigate the association with clinical response in 63 
different diseases such as rheumatoid arthritis (13), systemic lupus erythematosus (14), 64 
bronchial asthma (15), renal transplant rejection (16) and ulcerative colitis (17). For this reason, 65 
a pharmacodynamic approach using patients' PBMCs was set up, with the aim of investigating 66 
whether steroid sensitivity in vitro was associated with clinical response to steroid therapy in a 67 
well characterized cohort of pediatric patients with INS at onset. 68 
 69 
RESULTS 70 
Patients 71 
Between August 2011 and February 2014, 184 children were recruited by the pediatric 72 
departments participating in the trial. One hundred ten patients were excluded from the study for 73 
different reasons: non-adherence to the therapeutic protocol, the parents did not give written 74 
informed consent, onset of the disease occurred at weekends or holidays when it was not 75 
possible to send blood samples to the collecting center in Trieste, insufficient number of PBMCs 76 
obtained and cells not viable at arrival. Therefore, 74 patients (median age 4.33, IQR 2.82-7.23; 77 
63.5% male) were enrolled in the pharmacodynamic study. Differences between the two groups 78 
of patients were analyzed: the group of patients enrolled in the pharmacodynamic study was 79 
representative of the larger group (Supplementary Table). Blood was available for 68 patients at 80 
T0 (11 steroid resistant (SR), 26 frequent relapse-steroid dependent (FR-SD) and 31 no 81 
relapse-infrequent relapse (NR-IR)) and for 54 at T4 (9 SR, 18 FR-SD and 27 NR-IR); for 48 82 
patients (8 SR, 18 FR-SD and 22 NR-IR) the in vitro test was conducted at both time points (for 83 
definition of clinical classification see Table 1).  84 
 85 
In vitro sensitivity and clinical response to steroids 86 
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The in vitro lymphocyte sensitivity to methyl-prednisolone was evaluated and dose response 87 
curves obtained are shown in Figure 1. In vitro sensitivity was expressed as IC50 and Imax that 88 
displayed a wide interindividual variation both at T0 (IC50 median value 18.3 nM, IQR 4.5-79.7 89 
nM; Imax median value 95.5%, IQR 87.0-98.2%) and T4 (IC50 median value 12.4 nM, IQR 1.4-90 
205.2 nM; Imax median value 95%, IQR 88.5-98.7%). A significant correlation was found between 91 
in vitro parameters (IC50 and Imax) at T0 and T4 (Spearman test IC50 T0 vs Imax T0 p=2.9x10-6; 92 
Spearman test IC50 T4 vs Imax T4 p=2.2x10-5; Figure 2). No correlation was found between IC50 93 
or Imax values and gender, time to remission (39 patients within ten days and 35 after ten days) 94 
or total dose utilized. On the contrary, a correlation was evident between in vitro sensitivity to 95 
steroids and age at onset, with older patients showing higher in vitro resistance at T0 for methyl-96 
prednisolone Imax (p-value Spearman = 0.043, r = -0.25); univariate logistic regression analysis, 97 
considering steroid sensitive (SS: NR-IR and FR-SD) patients in comparison with steroid 98 
resistant (SR) subjects, showed that older patients at T0 were more resistant to steroid 99 
treatment (OR = 0.81, 95% CI = 0.67 - 0.98; p-value = 0.028; Supplementary Figure 1) 100 
 101 
In vitro sensitivity, at T0 and T4, and clinical response to steroids  102 
At T0, a trend was observed comparing SR versus SS patients: lower log-transformed Imax 103 
values at T0 were significantly associated with clinical steroid resistance (OR = 1.07, 95% CI = 104 
1.00 - 1.15; p-value logistic regression = 0.046; Supplementary Figure 2). However, this trend 105 
was not confirmed considering IC50 values. 106 
 107 
Moreover, univariate multinomial logistic regression showed a significant association between 108 
clinical and in vitro response at T4 comparing all groups (p-value IC50 = 0.015; Imax = 0.031; 109 
Figure 3). The most significant result was found at T4 comparing FR-SD patients vs NR-IR: FR-110 
SD showed lower log-transformed IC50 (OR = 0.48, 95% CI = 0.24 – 0.85; p-value = 0.0094; 111 
Figure 3). A similar pattern was evident for in vitro sensitivity represented as log-transformed Imax 112 
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values (OR = 1.13, 95% CI = 1.02 - 1.31; p-value = 0.017; Figure 3). ROC curves were 113 
constructed to assign optimal cut-off values for in vitro parameters significantly associated with 114 
clinical response. For IC50 at T4 an optimal cut-off of 4.4 nM could be defined. Area under the 115 
ROC curves was 74.1% (Figure 4). The test had a sensitivity of 66.6% and a specificity of 116 
77.7% (PPV = 60.9%; NPV = 81.9%). Logistic regression confirmed a lower proportion of NR-IR 117 
patients among those who reached the optimal cut-off point for IC50 (OR = 0.17, 95% CI = 0.04 118 
– 0.62; p-value = 0.009) in comparison with those who did not. A similar result was found also 119 
for Imax at T4: a unique optimal cut-off of 92.0% could be defined (AUC = 65.4%; sensitivity = 120 
88.9%, specificity = 44%; PPV = 51.6%; NPV = 85.7%) (Figure 4). Logistic regression confirmed 121 
a higher proportion of FR-SD patients among those who reached the optimal cut-off point for Imax 122 
(OR = 6.4, 95% CI = 1.44 – 45.7; p-value < 0.013) in comparison with those who did not. 123 
 124 
Differences between clinical groups considering the two time points pairwise were also 125 
analysed, however no significant correlation was found (Supplementary Figure 3). 126 
 127 
DISCUSSION 128 
This study was designed to investigate the possible association between in vitro response to 129 
methyl-prednisolone in PBMCs of pediatric patients with INS and their clinical response to 130 
steroids. The study was conducted prospectively, in a well characterized cohort of Italian 131 
pediatric patients treated with a shared therapeutic protocol, allowing for the evaluation of a 132 
large group of subjects, despite the relative rarity of the disease.  133 
The main result of this study is the increased in vitro response to steroid treatment in FR-SD 134 
patients after 4 weeks of therapy, both in terms of IC50 and Imax and optimal cut-off values were 135 
identified in this population. These results could be clinically useful for understanding which 136 
subjects are at greater risk of becoming steroid dependent or relapse frequently, defining the 137 
severity of the steroid dependence during the initial treatment period and evaluating the need for 138 
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a second immunosuppressive drug. A further outcome of this study was the lower in vitro 139 
sensitivity of SR patients, evaluated as Imax at disease onset.  140 
Literature data (17, 18) show that in vitro PBMC sensitivity to dexamethasone could be 141 
considered a predictor of response to treatment in various diseases (13-17, 19). Carlotti et al. 142 
also used this assay in INS patients, however, due to the small number of patients enrolled, no 143 
definitive data were obtained (20). In this study, methyl-prednisolone was used instead of 144 
dexamethasone because prednisone, a prednisolone prodrug, is currently used in INS. Previous 145 
studies conducted in our laboratory have shown that the lymphocyte suppression test can be 146 
safely performed with methyl-prednisolone and that this agent gives more consistent results 147 
than prednisolone (21); moreover literature data showed that this test has a low inter- and intra-148 
assay variation (18) allowing us to consider this assay useful for the study and prospectively for 149 
routine application in the clinical setting. A considerable interindividual variability for in vitro 150 
steroid sensitivity was evident in our population as already reported in various diseases and in 151 
healthy subjects (18,22). The increased in vitro response at T4 observed in FR-SD patients was 152 
quite unexpected; a correlation between relapses and hypothalamic–pituitary–adrenal (HPA) 153 
axis suppression has been already demonstrated (23,24). Relapses in INS are often triggered 154 
by infection (25). Viral infections induce the release of cytokines, in particular interleukin (IL)2, 4 155 
and 13 (26), that are in part responsible for proteinuria. In patients who are extremely sensitive 156 
to these agents, and hence have an increased HPA suppression, the reduced endogenous 157 
steroid production when steroid therapy is discontinued could not be enough to reduce cytokine 158 
release; this would result in INS relapse and steroid dependency.  159 
Apart from rare cases of severe steroid dependence, SD subjects are normally diagnosed only 160 
after several weeks of treatment. Indeed, glucocorticoid treatment of INS in this study involves 4 161 
or 6 weeks of initial therapy with 60 mg/m2/day, followed by a 16-weeks tapering. Moreover, 162 
other frequently used steroid regimens in the treatment of a first episode of INS (27, 28) also 163 
involve very long treatment (6 weeks of full-dose 60 mg/m2 treatment + 6 weeks of alternate day 164 
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40 mg/m2 treatment). Interestingly, the use of the described in vitro test could help in defining 165 
the severity of the steroid dependence after only 4 weeks of therapy, allowing to evaluate the 166 
need for a second immunosuppressive drug. For SR patients, reduced in vitro response at T0 167 
could be used to shorten the duration of the steroid treatment necessary for the definition of 168 
steroid resistance (at least 8 weeks according the KDIGO guidelines) (3), thus resulting in the 169 
possibility to perform biopsy, genetic testing and introduce other immunosuppressive drugs 170 
earlier, as previously demonstrated in other diseases (13-17).  171 
Among the prognostic indicators of clinical outcome, age at onset of the disease has been 172 
proposed by various authors; steroid resistance is seen more often in adolescents (29-32), 173 
whereas young age at diagnosis (1-6 years of age) has been associated with better steroid 174 
response (8, 9); in line with these studies, similar results were obtained in our cohort of patients. 175 
On the contrary, we did not find any association between gender or clinical course of the 176 
disease, in terms of risk of relapses or steroid dependence, as reported by others (9, 33). 177 
A limitation of this study is the number of patients enrolled; however, pediatric INS is a relatively 178 
rare disease and this is a prospective study on a special population (children) that could provide 179 
important and innovative insights. Moreover, another limitation was the lack of a clear cut-off 180 
value for the in vitro sensitivity test for distinguish SR patients at T0: this is probably due to low 181 
frequency of SR patients, and results from a larger cohort are needed. 182 
In conclusion, the results of the in vitro test, associated with other clinical and laboratory 183 
parameters, if confirmed, could help clinicians in the choice of more personalised steroid 184 
treatments and represent an incentive for the future exploration of steroid sensitivity in pediatric 185 
INS patients. 186 
 187 
METHODS 188 
The pharmacodynamics of steroids was studied in a cohort of patients with INS at onset, 189 
recruited for a prospective multicenter Italian trial on the treatment of INS (ClinicalTrials.gov Id.: 190 
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NCT01386957). In brief, children with a first episode of INS, presenting at 49 Pediatric and 191 
Pediatric Nephrology Units in 10 Italian regions, were treated with prednisone at a dose of 60 192 
mg/m2/day for either 4 or 6 weeks, depending on whether time to remission was < or ≥ 10 days. 193 
Steroids were then tapered over a 16 weeks period. Total prednisone dosage was 2828 mg/m2 194 
in subjects achieving remission within ten days, 3668 mg/m2 in the others. Patients were 195 
classified into 2 groups: steroid resistant (SR) and steroid sensitive (SS). SS subjects were 196 
further stratified into frequent relapse-steroid dependent subjects (FR-SD) and no relapse-197 
infrequent relapse subjects (NR-IR), as defined in Table 1. 198 
All the recruited children were admitted to hospital. The parents of all the participating children 199 
gave written informed consent before the study began. Ethics committee approval was obtained 200 
from all the participating centers. 201 
Sample size has been determined as described in the supplementary material. 202 
Peripheral blood, anticoagulated with EDTA (8 ml), was collected before starting therapy (T0) 203 
and after 4 weeks of prednisone treatment (T4). Blood samples were sent at temperature of 4°C 204 
to the collecting center at the University of Trieste and processed within 24 hours from 205 
collection.  206 
 207 
In vitro proliferation assay 208 
The effect of methyl-prednisolone on the proliferation of PBMCs was determined by labeling 209 
metabolically active cells with [methyl-3H] thymidine (PerkinElmer, Milan, Italy) as previously 210 
reported (21). PBMCs were collected by density gradient centrifugation on Ficoll PaqueTM Plus 211 
(Healthcare, Milan, Italy), resuspended in complete RPMI-1640 medium containing 212 
Concanavalin-A (5 μg/ml) and seeded into 96 well round bottom plates (2×105 cells/well) in the 213 
presence of methyl-prednisolone (range from 0.05 nM to 54 μM) (34). After 50 hours of 214 
incubation, cells were pulsed with [methyl-3H] thymidine (final concentration of 2.5 μCi/ml) and 215 
incubation was continued for an additional 22 hours. The radioactivity of the samples was 216 
 10 
 
determined by a Liquid Scintillation Analyzer (Wallac 1450 Microbeta liquid scintillation counter, 217 
PerkinElmer, Milan, Italy). Raw count per minute (cpm) data were converted and normalized to 218 
percent of maximal survival for each experimental condition (cpm methyl-prednisolone/cpm 219 
control*100). Non linear regression of dose–response data was performed using Graph-Pad 220 
Prism version 4.00 for computing IC50, the methyl-prednisolone concentration required to reduce 221 
proliferation to 50%. Imax was also calculated and defined, according to previous studies on 222 
glucocorticoids (18), as the maximum percentage inhibition of thymidine incorporation achieved 223 
at the highest concentration of methyl-prednisolone (54 µM) tested. 224 
Imax and IC50 data at T0 and T4 were compared between subjects with different clinical 225 
responses to treatment (SR vs SS subjects) or with a different clinical outcome of the disease 226 
(NR, IR, FR and SD subjects). Moreover, gender, age at disease onset and time to remission 227 
were evaluated and compared with the pharmacodynamic data. 228 
 229 
Statistical analysis 230 
For continuous variables, normality of distribution was assessed by means of visual examination 231 
of the data plot and a Shapiro test. Logarithmic transformation was applied to normalize 232 
distribution and/or reduce variance. The correlation between continuous variables was 233 
assessed using the appropriate parametric (Pearson) and non parametric (Spearman) tests. 234 
Any possible association between methyl-prednisolone IC50, Imax and clinical variables 235 
(response, time to remission, age at the onset of disease and sex) was investigated using 236 
univariate logistic regression models. Receiver operating characteristic (ROC) curves were 237 
constructed for the significant in vitro tests to determine the optimal cut-off value for 238 
discriminating between patients’ clinical response to steroid treatment. Sensitivity, specificity, 239 
and the positive and negative predictive values (PPV, NPV, respectively) of the cut-off point 240 
were analyzed. Logistic regression, considering the proportion of patients achieving the 241 
predicted clinical response, comparing patients who reached the optimal cut-off point and those 242 
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who did not, was used to confirm the significance of the cut-off values. Statistical analyses were 243 
performed using the software R. 244 
P values lower than 0.05 were considered statistically significant. Odds Ratio (OR) and 95% 245 
confidence interval (95% CI) were calculated for all the analyses. 246 
 247 
STUDY HIGHLIGHTS 248 
What is the current knowledge on the topic?  249 
Children with INS are treated with steroids: some patients are initially steroid resistant and other 250 
became steroid dependent despite initial complete remission. To date, the mechanisms of 251 
steroid resistance and/or dependence are scarcely understood and there is no means to predict 252 
the response in advance. 253 
What question did this study address?  254 
In the present study, we investigated the in vitro steroid sensitivity in patients with INS, in order 255 
to elucidate whether this test could predict the efficacy of the treatments. 256 
What this study adds to our knowledge?  257 
The in vitro steroid susceptibility test at T4 shows a direct correlation between steroid 258 
dependence and in vitro response, while, at T0, an inverse correlation between steroid 259 
resistance and in vitro methyl-prednisolone response is evident. 260 
How this might change clinical pharmacology and therapeutics? 261 
Knowing in advance the response to steroid treatment is a field of particular interest, especially 262 
in young children to reduce ineffective treatments and side effects. This test could be useful to 263 
predict steroid response in pediatric patients with INS undergoing this treatment. 264 
 265 
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FIGURES/TABLE LEGENDS 385 
Figure 1: In vitro dose-response curves for the various subpopulations : a) SR, FR-SD and NR-IR at T0; b) SR, FR-386 
SD and NR-IR at T4. In vitro response is plotted in Log10 scale. 387 
 388 
Figure 2. Scatter plot displaying drug sensitivity (IC50 and Imax) at Time 0 (T0) and T4. In vitro response is plotted in 389 
Log10 scale. The correlation between continuous variables was assessed using Spearman tests. A significant 390 
correlation was found between in vitro parameters (IC50 and Imax) at T0 and T4 (Spearman test IC50 T0 and Imax T0 391 
p=2.9x10-6; Spearman test IC50 T4 and Imax T4 p=2.2x10-5.  392 
 393 
 394 
Figure 3: Box plot comparing in vitro and clinical response at T4 between the three groups of patients. In vitro 395 
response is plotted in Log10 scale. The bold horizontal line represents the distribution mean. Statistical significance 396 
was assessed by carrying out logistic regression analysis. A significant association was found for log-transformed IC50 397 
values (p-value = 0.015) and for log-transformed Imax (p-value = 0.031). A significant association was also found for 398 
log-transformed IC50 values comparing FR-SD patients and NR-IR patients (p-value = 0.0094) and for log-399 
transformed Imax values (p-value = 0.017) 400 
 401 
Figure 4: Areas under the ROC curves of IC50 (left panel) and Imax (right panel) among 27 NR-IR and 18 FR-SD 402 
patients after 4 weeks of treatment with prednisone for a first episode of INS; ROC, receiver operating characteristic. 403 
Optimal cut-off value was for IC50 4.4 nM (sensitivity 66.6%, specificity 77.7%, positive predicting value (PPV) and 404 
negative predicting value (NPV) 60.9% and 81.9% respectively) and for Imax 92.0% (sensitivity 89%, specificity 44%, 405 
PPV 51.6% and NPV 85.7%). 406 
 407 
 408 
 409 
Table 1: Definition of clinical response used in the text. 410 
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Supplementary	Table	
		 N°	patients	 M		(%)	
F		
(%)	
M:F	
ratio	
median	age	
(range)		
NR-IR	
(%)	
CD-FR	
(%)	
CR	
(%)	
All	patients	 184	 120	(65%)	
64	
(35%)	 1,87	 3,9	(0,6-17)	 90	(49%)	 73	(40%)	 21	(11%)	
Patients	with	in	vitro	
sensitivity	test	
available	
74	 47	(64%)	
27	
(36%)	 1,74	 4,3	(1,0-17)	 36	(48)%	 26	(35%)	 12	(16%)	
Supplementary	 Table:	 Differences	 between	 the	 whole	 group	 of	 patients	 enrolled	 and	 the	 patients	 enrolled	 in	 the	
pharmacodynamics	study.	
	
Supplementary	Figure	1	
	
Supplementary	Figure	1:	Box	plot	comparing	age	at	disease	onset	and	clinical	response.	Age	at	onset	of	disease	is	plotted	in	Log10	
scale.	Statistical	significance	was	assessed	by	carrying	out	logistic	regression	analysis.	A	significant	association	was	found	(p-value	=	
0.028).	
	
Supplementary	Figure	2	
	
Supplementary	Figure	2:	Box	plot	comparing	 in	vitro	and	clinical	 response	between	steroid	sensitive	 (SS)	versus	steroid	resistant	
(SR)	 patients.	 In	 vitro	 response	 is	 plotted	 in	 Log10	 scale.	 The	 bold	 horizontal	 line	 represents	 the	 distribution	median.	 Statistical	
significance	 was	 assessed	 by	 carrying	 out	 logistic	 regression	 analysis.	 A	 correlation	 was	 found	 for	 log-transformed	 Imax	 values	
comparing	SR	vs	SS	(p-value	=	0.046).		
Supplementary	Figure	3	
	
	
Supplementary	 figure	3:	Box	plot	 comparing	differences	between	clinical	groups	 (NR-IR,	 	 SD-FR	and	SR)	 considering	 the	changes	
between	T0	and	T4.	Any	significant	differences	were	found	(IC50	NR-IR	T0	vs	T4	Wilcoxon	test	p-value	=	0.61,	Imax	NR-IR	T0	vs	T4	
Wilcoxon	test	p-value	=	0.33;	IC50	SD-FR	T0	vs	T4	Wilcoxon	test	p-value	=	0.08,	Imax	SD-FR	T0	vs	T4	Wilcoxon	test	p-value	=	0.063;	
IC50	SR	T0	vs	T4	Wilcoxon	test	p-value	=	0.64,	Imax	SR	T0	vs	T4	Wilcoxon	test	p-value	=	0.45)	
	
Sample	size	determination	
Sample	 size	was	 determined	 by	 average	 enrollment	 of	 the	NEFROKID	 consortium	 (60-80	 patient/year).	 Considering	 that	 due	 to	
technical	 issues	50%	of	patients	enrolled	would	be	available	 for	 the	pharmacodynamics	analysis,	with	a	 study	 length	of	2	years,	
around	 80	 samples	 would	 be	 analyzed.	Moreover,	 considering	 a	 frequency	 of	 glucocorticoid	 resistant	 patients	 of	 10-15%,	 this	
study,	therefore	enrolling	10	resistant	and	70	sensitive	patients,	would	be	sufficiently	powered	(p	=	0.05,	power	=	80%),	to	detect	a	
difference	of	in	vitro	sensitivity	parameters	between	sensitive	and	resistant	patients	of	strong	magnitude	(ratio	between	difference	
of	means	and	pooled	standard	deviation	=	0.96).	Considering	a	frequency	of	glucocorticoid	dependence	(SD+FR)	of	50%	of	sensitive	
patients,	this	study,	enrolling	35	SD+FR	and	35	NR+IR	patients,	would	be	sufficiently	powered	(p	=	0.05,	power	=	80%)	to	detect	a	
difference	 of	 in	 vitro	 sensitivity	 parameters	 between	 SD+FR	 and	 NR+IR	 patients	 of	 at	 least	medium	magnitude	 (ratio	 between	
difference	of	means	and	pooled	standard	deviation	=	0.67).	
